Stock Financial Ratios

NVET / Nexvet Biopharma plc financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)79.17
Enterprise Value ($M)14.47
Book Value ($M)35.14
Book Value / Share3.05
Price / Book3.79
NCAV ($M)35.28
NCAV / Share3.06
Price / NCAV1.30
Income Statement (mra) ($M)
Net Income-19.36
Balance Sheet (mrq) ($M)
Cash & Equivalents14.52
Cash / Share1.26
Quick Ratio6.93
Current Ratio6.93
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.55
Return on Assets (ROA)-0.78
Return on Equity (ROE)-0.55
Identifiers and Descriptors
Central Index Key (CIK)1618561
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)11.92
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Net Per Share0.44
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Inventory Raw Materials Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share1.82
Minority Interest Per Share0.00
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Cash And Equivalents Per Share1.26
Debt Per Share0.00
Property Plant And Equipment Per Share0.44
Retained Earnings Per Share-5.17
Assets Current Per Share1.65
Inventory Per Share0.00
Liabilities And Stock Equity Per Share2.15
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Additional Paid In Capital Per Share7.28
Liabilities Per Share0.33
Goodwill Per Share0.00
Assets Per Share2.15
Liabilities Current Per Share0.31
Assets Other Current Per Share0.02
Cash Per Share1.26

Related News Stories

The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis

22h zacks
Chicago, IL – Jan 19, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Johnson & Johnson (JNJ - Free Report) , AbbVie (ABBV - Free Report) , Amgen Inc. (AMGN - Free Report) , Novo-Nordisk (NVO - Free Report)  and Zoetis (ZTS - Free Report) . (200-0)

Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?

2018-01-18 zacks
Investing in sound large-cap pharma stocks seems judicious as they are fundamentally lucrative and ensure a steady stream of cash inflows for the investor. (146-0)

Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View

2017-11-02 zacks
Zoetis Inc. (ZTS - Free Report) third-quarter 2017 earnings of 65 cents per share increased 25% year over year on a reported as well as operational (excluding foreign impact) basis and beat the Zacks Consensus Estimate of 63 cents. The year-over-year increase in earnings was primarily due to the company’s focus on controlling cost of goods and expenses. (76-1)

Zoetis (ZTS) Q3 Earnings & Sales Beat Estimate; 2017 View Up

2017-11-02 zacks
Florham Park, NJ-based Zoetis Inc. (ZTS - Free Report) is one of the leading global animal health companies focused on the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company came into existence following Pfizer’s decision to spin off its animal health business in 2013. (102-0)

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

2017-10-30 zacks
Zoetis Inc. (ZTS - Free Report) is scheduled to report third-quarter 2017 results on Nov 2 before the market opens. (111-0)

CUSIP: G6503X109